Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: blood draw, Gene sequencing.
- Who it may be relevant to
- Registry conditions: Lung Cancer - Non Small Cell, EGFR Exon 19 Deletion Mutation. Basic parameters: 18 years — 100 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
EGFR gene mutations are some of the most commonly occurring mutations in non-small cell lung cancer. Investigators have developed a DNA instability model that estimates a risk score to assess the likelihood of an individual acquiring a cancer-linked mutation. The aim of this study is to collect blood from both those diagnosed with EGFR positive lung cancer and healthy individuals, evaluate their gene sequence surrounding the EGFR landscape and use the cancer positive and healthy sequences to validate the risk assessment model, which may one day be used to provide insight on susceptibility of getting EGFR positive lung cancer or potentially other cancer types.
Interventions
- Other blood draw
A 10ml Blood sample will be taken and used to sequence the EGFR gene and surrounding DNA. - Other Gene sequencing
Subjects will have their DNA sequenced within and around the EGFR gene.
Primary outcome measures
- Differences in DNA sequence of EGFR gene [Time frame: From enrollment to end of data analysis at 6 months]
Eligibility criteria
Inclusion criteria
- 18-100 years old
- Biologically born female
- Diagnosed with EGFR positive lung cancer (Arm 1-Cancer group)
- No cancer diagnosis (Arm 2-health control)
Exclusion criteria
- less than 18 years of age
- Biologically born male
- Incarcerated at the time of participation
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
United States · 1 center
- Our Lady of the Lake Regional Medical Center — Baton Rouge
Identifiers
NCT: NCT06659458 · LSUHSCIRB_7781